FOLR1 and ovarian cancer: In contrast, mirvetuximab soravtansine (MIRV), or Elahere (ImmunoGen), the first FRα-targeting antibody-drug conjugate (ADC), has recently been approved by the US FDA to treat platinum-resistant ovarian cancer (11).